Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16590
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorALONSO ABAD, Ariel-
dc.contributor.authorVAN DER ELST, Wim-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.contributor.authorBUYSE, Marc-
dc.date.accessioned2014-04-04T10:03:03Z-
dc.date.available2014-04-04T10:03:03Z-
dc.date.issued2013-
dc.identifier.citationCLINICAL INVESTIGATION, 3 (12), p. 1147-1155-
dc.identifier.issn2041-6792-
dc.identifier.urihttp://hdl.handle.net/1942/16590-
dc.description.abstractSurrogate end point evaluation has received a lot of attention for approximately a quarter of a century. Throughout this time, the topic has been surrounded with both hopes and perils. The history of the evaluation of surrogate end point evaluation is described, from Prentice’s definition, via single-trial evaluation to meta-analytic approaches. While based on technical developments and advances in statistical methodology, the treatment of the topic here is largely nontechnical. A perspective is given as to what might be a sensible way forward. It is clear that statistical evaluation can offer a contribution to the discussion as to whether a surrogate will be adopted and in what form, but can never be seen as the sole decision maker. While there is room for the adoption of surrogates, it is very important that pitfalls and drawbacks be kept in mind at all times.-
dc.language.isoen-
dc.rights© 2013 Future Science Ltd.-
dc.subject.otheradjusted association; biomarker; causal inference; information theory; meta-analytic framework; proportion explained; surrogate end point; surrogate marker; surrogate threshold effect-
dc.titleReview: Clinical Trial Methodology: Surrogate endpoints: when should they be used?-
dc.typeJournal Contribution-
dc.identifier.epage1155-
dc.identifier.issue12-
dc.identifier.spage1147-
dc.identifier.volume3-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.identifier.vabbc:vabb:378901-
dc.identifier.doi10.4155/CLI.13.105-
item.fulltextWith Fulltext-
item.contributorMOLENBERGHS, Geert-
item.contributorALONSO ABAD, Ariel-
item.contributorVAN DER ELST, Wim-
item.contributorBURZYKOWSKI, Tomasz-
item.contributorBUYSE, Marc-
item.fullcitationMOLENBERGHS, Geert; ALONSO ABAD, Ariel; VAN DER ELST, Wim; BURZYKOWSKI, Tomasz & BUYSE, Marc (2013) Review: Clinical Trial Methodology: Surrogate endpoints: when should they be used?. In: CLINICAL INVESTIGATION, 3 (12), p. 1147-1155.-
item.accessRightsRestricted Access-
item.validationvabb 2019-
crisitem.journal.issn2041-6792-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Molenberghs Rev.pdf
  Restricted Access
Published version2.84 MBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.